The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Angiogenesis of Breast Cancer
Open accessAbstract
Angiogenesis, the process of new blood vessel formation, plays a central role in both local tumor growth and distant metastasis in breast cancer. Extensive laboratory data suggest that angiogenesis plays an essential role in breast cancer development, invasion, and metastasis. Hyperplastic murine breast papillomas and histologically normal lobules adjacent to cancerous breast tissue support angiogenesis in preclinical models, suggesting that angiogenesis precedes transformation of mammary hyperplasia to malignancy. Transfection of tumor cells with angiogenic stimulatory peptides has been shown to increase tumor growth, invasiveness, and metastasis. Conversely, transfection of tumor cells with inhibitors of angiogenesis decreases growth and metastasis. The matrix metalloproteinase (MMP) family of enzymes degrades the basement membrane and extracellular matrix and is associated with a family of endogenous inhibitors, tissue inhibitors ofmetalloproteinases (TIMPs). Under normal physiologic conditions, the MMPs and TIMPs exist in anexquisitebalance.Thisbalance isdisrupted during active angiogenesis. Expression of MMPs increases with the progression from benign to preinvasive, invasive, and metastatic breast cancer and is associated with increasing histologic tumor grade. Microscopic metastases are growth restricted and remain dormant until they undergo an angiogenic switch, presumably a result of further mutation. This angiogenic switch often results in increased expression of MMPs. Hypoxia is a key signal for the induction of angiogenesis. Hypoxia-inducible factors (HIF-1 and HIF-2) are heterodimeric transcription factors consisting of and subunits. The subunit is constitutively expressed while the subunit is protected from degradation only under hypoxic condition. HIF-1 expression progressively increases from normal breast tissue to usual ductal hyperplasia to ductal carcinoma-insitu to invasive ductal carcinoma. HIF-1 expression is higher in poorly differentiated than in well-differentiated lesions and is associated with increased proliferation and expression of the estrogen receptor and vascular endothelial growth factor (VEGF). Similarly, expression of carbonic anhydrase IX, an HIF-1 -dependant enzyme important in pH regulation, is associated with worse relapse-free and overall survival in patients with invasive breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Asahara, T., Masuda, H., Takahashi, T., Kalka, C., Pastore, C., Silver, M., Kearne, M., Magner, M., & Isner, J. M. (1999) · Circulation Research · doi:10.1161/01.res.85.3.221 · Cited by 3,253
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E. N., Moore, D. H., Meli, S., & Gasparini, G. (1992) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/84.24.1875 · Cited by 1,775
Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
Salceda, S., & Caro, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22642 · Cited by 1,674
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
Hypoxia-inducible expression of tumor-associated carbonic anhydrases.
Wykoff, C. C., Beasley, N. J. P., Watson, P. H., Turner, K., Pastorek, J., Sibtain, A., Wilson, G. D., Turley, H., Talks, K., Maxwell, P. H., et al. (2000) · PubMed · Cited by 1,491
Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
Wood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 845
Petit, A. M. V., Rak, J. W., Hung, M., Rockwell, P., Goldstein, N. I., FENDLY, B. M., & Kerbel, R. S. (1997) · Europe PMC (PubMed Central) · Cited by 836
Relf, M., LeJeune, S., Scott, P. A. E., Fox, S. B., Smith, K. A., Leek, R., Moghaddam, A., Whitehouse, R. M., Bicknell, R., & Harris, A. L. (1997) · PubMed · Cited by 833
Genetic instability and darwinian selection in tumours
Cahill, D. P., Kinzler, K. W., Vogelstein, B., & Lengauer, C. (1999) · Trends in Cell Biology · doi:10.1016/s0962-8924(99)01661-x · Cited by 748
Hattori, K., Dias, S., Heissig, B., Hackett, N. R., Lyden, D., Tateno, M., Hicklin, D. J., Zhu, Z., Witte, L., Crystal, R. G., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.9.1005 · Cited by 687
Vasculogenic Mimicry and Tumor Angiogenesis
Folberg, R., Hendrix, M. J. C., & Maniotis, A. J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64739-6 · Cited by 684
Pluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi, T., di Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B., Berk, D. A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081626898 · Cited by 603
Levels of Hypoxia-Inducible Factor-1 During Breast Carcinogenesis
Bos, R., Zhong, H., Hanrahan, C. F., Mommers, E. C. M., Semenza, G. L., Pinedo, H. M., Abeloff, M. D., Simons, J. W., van Diest, P. J., & van der Wall, E. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.309 · Cited by 593
Bruns, C. J., Solórzano, C. C., Harbison, M. T., Ozawa, S., Tsan, R. Z., Fan, D., Abbruzzese, J. L., Traxler, P. M., Buchdunger, E., Radinsky, R., et al. (2000) · PubMed · Cited by 532
Colleoni, M., Rocca, A., Sandri, M. T., Zorzino, L., Masci, G., Nolè, F., Peruzzotti, G., Robertson, C., Orlando, L., Cinieri, S., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf013 · Cited by 496
Gasparini, G., Bonoldi, E., Gatti, C., Vinante, O., Toi, M., Tominaga, T., Gion, M., Dittadi, R., Verderio, P., Boracchi, P., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.2.139 · Cited by 494
Using GFP in FRET-based applications
Pollok, B. (1999) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01434-2 · Cited by 480
Bocci, G., Nicolaou, K. C., & Kerbel, R. S. (2002) · PubMed · Cited by 444
Chia, S. K., Wykoff, C. C., Watson, P. H., Han, C., Leek, R. D., Pastorek, J., Gatter, K. C., Ratcliffe, P., & Harris, A. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3660 · Cited by 432
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
Bocci, G., Francia, G., Man, S., Lawler, J., & Kerbel, R. S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135406100 · Cited by 414
Kunkel, P., Ulbricht, U., Böhlen, P., Brockmann, M. A., Fillbrandt, R., Stavrou, D., Westphal, M., & Lamszus, K. (2001) · PubMed · Cited by 399
Redefining the Target: Chemotherapeutics as Antiangiogenics
Miller, K. D., Sweeney, C. J., & Sledge, G. W. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1195 · Cited by 395
Self-citationA cancer therapy resistant to resistance
Kerbel, R. S. (1997) · Nature · doi:10.1038/36978 · Cited by 369
Slaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P., & Fidler, I. J. (1999) · PubMed · Cited by 337
Sweeney, C. J., Miller, K. D., Sissons, S. E., Nozaki, S., Heilman, D. K., Shen, J., & Sledge, G. W. (2001) · PubMed · Cited by 331
Self-citationLymphoma-Specific Genetic Aberrations in Microvascular Endothelial Cells in B-Cell Lymphomas
Streubel, B., Chott, A., Huber, D., Exner, M., Jäger, U., Wagner, O., & Schwarzinger, I. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033153 · Cited by 318
Konecny, G. E., Meng, Y. G., Untch, M., Wang, H.-J., Bauerfeind, I., Epstein, M., Stieber, P., Vernes, J.-M., Gutierrez, J., Hong, K., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0951-3 · Cited by 318
Krippl, P., Langsenlehner, U., Renner, W., Yazdani‐Biuki, B., Wolf, G., Wascher, T. C., Paulweber, B., Haas, J., & Samonigg, H. (2003) · International Journal of Cancer · doi:10.1002/ijc.11238 · Cited by 316
Drevs, J., Hofmann, I., Hugenschmidt, H., Wittig, C., Madjar, H., Müller, M., Wood, J. M., Martiny‐Baron, G., Unger, C., & Marmé, D. (2000) · PubMed · Cited by 308
Murray, L. J., Abrams, T. J., Long, K. R., Ngai, T. J., Olson, L. M., Hong, W., Keast, P. K., Brassard, J. A., O'Farrell, A. M., Cherrington, J. M., et al. (2003) · Clinical & Experimental Metastasis · doi:10.1023/b:clin.0000006873.65590.68 · Cited by 305
Maity, A. M., Pore, N., Lee, J. S. H., Solomon, D., & O’Rourke, D. M. (2000) · PubMed · Cited by 302
Foekens, J. A., Peters, H. A., Grebenchtchikov, N. I., Look, M. P., Gelder, M. E. M., Geurts-Moespot, A. J., van der Kwast, T., Sweep, F. C. G. J., & Klijn, J. G. M. (2001) · PubMed · Cited by 296
Microvessel Density and Distribution in Ductal Carcinoma In Situ of the Breast
Guidi, A. J., Fischer, L., Harris, J. R., & Schnitt, S. J. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.8.614 · Cited by 284
Berlin, L. (1998) · American Journal of Roentgenology · doi:10.2214/ajr.170.2.9456928 · Cited by 272
Sparano, J. A., Bernardo, P., Stephenson, P., Gradishar, W. J., Ingle, J. N., Zucker, S., & Davidson, N. E. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.054 · Cited by 269
Patan, S., Munn, L. L., & Jain, R. K. (1996) · Microvascular Research · doi:10.1006/mvre.1996.0025 · Cited by 266
Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.
Teicher, B. A., Sotomayor, E. A., & Huang, Z. D. (1992) · PubMed · Cited by 260
Abrams, T. J., Murray, L. J., Pesenti, E. A., et al. (2003) · PubMed · Cited by 251
Kerbel, R. S., Yu, J., Tran, J., Man, S., Viloria-Petit, A., Klement, G., Coomber, B. L., & Rak, J. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1013172910858 · Cited by 237
Vascular remodelling during the normal and malignant life cycle of the mammary gland
Djonov, V., Andres, A., & Ziemiecki, A. (2001) · Microscopy Research and Technique · doi:10.1002/1097-0029(20010115)52:2<182::aid-jemt1004>3.0.co;2-m · Cited by 220
Stessels, F., Van den Eynden, G., Van der Auwera, I., Salgado, R., Van den Heuvel, E., Harris, A. L., Jackson, D. G., Colpaert, C. G., Van Marck, E. A., Dirix, L. Y., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601727 · Cited by 214
Miller, K. D., Trigo, J. M., Wheeler, C., Barge, A., Rowbottom, J., Sledge, G., & Baselga, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1923 · Cited by 198
Self-citationInhibition of angiogenesis by antiestrogens.
Gagliardi, A., & Collins, D. C. (1993) · PubMed · Cited by 179
Angiogenesis: A Marker for Neoplastic Transformation of Mammary Papillary Hyperplasia
Brem, S. S., Gullino, P. M., & Medina, D. (1977) · Science · doi:10.1126/science.402692 · Cited by 156
Gohongi, T., Fukumura, D., Boucher, Y., Yun, C., Soff, G. A., Compton, C. C., Todoroki, T., & Jain, R. K. (1999) · Nature Medicine · doi:10.1038/13524 · Cited by 144
Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas
Passalidou, E., Trivella, M., Singh, N., Ferguson, M. L., Hu, J., Cesario, A., Granone, P. L., Nicholson, A. G., Goldstraw, P. G., Ratcliffe, C., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600015 · Cited by 125
Angiogenesis Induced by "Normal" Human Breast Tissue: A Probable Marker for Precancer
Jensen, H. M., Chen, I., DeVault, M. R., & Lewis, A. E. (1982) · Science · doi:10.1126/science.6181563 · Cited by 122
Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth.
Haran, E. F., Maretzek, A., Goldberg, I. D., Horowitz, A., & Degani, H. (1994) · PubMed · Cited by 121
Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances
Wiseman, H. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90283-6 · Cited by 117
Scappaticci, F. A., Smith, R., Pathak, A., Schloss, D. J., Lum, B. L., Cao, Y., Johnson, F. L., Engleman, E. G., & Nolan, G. P. (2001) · Molecular Therapy · doi:10.1006/mthe.2000.0243 · Cited by 114
The combination of antiagniogenic agents to inhibit primary tumor growth and metastasis
Brem, H., Gresser, I., Grosfeld, J. A., & Folkman, J. (1993) · Journal of Pediatric Surgery · doi:10.1016/s0022-3468(05)80308-2 · Cited by 110
Vascular Morphogenesis and Remodeling in a Human Tumor Xenograft
Patan, S., Tanda, S., Roberge, S., Jones, R. C., Jain, R. K., & Munn, L. L. (2001) · Circulation Research · doi:10.1161/hh2001.097872 · Cited by 92
Clarke, K., Smith, K. J., Gullick, W., & Harris, A. L. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1805 · Cited by 89
Low, J. A., Johnson, M. D., Bone, E. A., & Dickson, R. B. (1996) · PubMed · Cited by 87
Neoplastic Angiogenesis — Not All Blood Vessels Are Created Equal
Fidler, I. J., & Ellis, L. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048080 · Cited by 78
Prognostic Value of Residual Node Involvement in Operable Breast Cancer after Induction Chemotherapy
Curé, H., Amat, S., Penault-Llorca, F. M., Bouëdec, G. L., Ferrière, J.-P., Mouret‐Reynier, M., Kwiatkowski, F., Feillel, V., Dauplat, J., & Chollet, P. J. M. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1020274709327 · Cited by 74
Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors.
Gagliardi, A. R., Hennig, B., & Collins, D. C. (1996) · PubMed · Cited by 74
Contribution of Transient Blood Flow to Tumour Hypoxia in Mice
Durand, R. E., & LePard, N. E. (1995) · Acta Oncologica · doi:10.3109/02841869509093982 · Cited by 69
Vasculogenesis Plays a Role in the Growth of Ewing's Sarcoma in Vivo.
Bolontrade, M. F., Zhou, R., & Kleinerman, E. S. (2002) · PubMed · Cited by 66
A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer
Miller, K. D., Gradishar, W. J., Schuchter, L. M., Sparano, J. A., Cobleigh, M., Robert, N. J., Rasmussen, H. S., & Sledge, G. W. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf199 · Cited by 64
Self-citationWild, R., Dings, R. P. M., Subramanian, I. V., & Ramakrishnan, S. (2004) · International Journal of Cancer · doi:10.1002/ijc.20100 · Cited by 55
Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC)
Hainsworth, J. D., Sosman, J. A., Spigel, D. R., Schwert, R. C., Carrell, D. L., Hubbard, F. J., & Greco, F. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.4502 · Cited by 55
Koukourakis, M. I., Giatromanolaki, A. N., O'Byrne, K. J., Cox, J., Krammer, B. E., Gatter, K. C., & Harris, A. L. (1999) · Clinical & Experimental Metastasis · doi:10.1023/a:1006780710148 · Cited by 49
Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation
Heffelfinger, S. C., Yan, M., Gear, R. B., Schneider, J., LaDow, K., & Warshawsky, D. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700128 · Cited by 29
(1993) · International Journal of Cancer · doi:10.1002/ijc.2910530330 · Cited by 11
(2001) · PubMed
Cited by
Kuhl, C. (2007) · Radiology · doi:10.1148/radiol.2442051620 · Cited by 778
An overview of triple-negative breast cancer
Kumar, P., & Aggarwal, R. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3859-y · Cited by 771
Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
Shih, T., & Lindley, C. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.015 · Cited by 521
Single-breath-hold photoacoustic computed tomography of the breast
Lin, L., Hu, P., Shi, J., Appleton, C. M., Maslov, K., Li, L., Zhang, R., & Wang, L. V. (2018) · Nature Communications · doi:10.1038/s41467-018-04576-z · Cited by 454
Morabito, A., De Maio, E., Di Maio, M., Normanno, N., & Perrone, F. (2006) · The Oncologist · doi:10.1634/theoncologist.11-7-753 · Cited by 274
Metadata
- Authors
- Schneider, B. P., & Miller, K. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-03-10
- Volume
- 23
- Issue
- 8
- Pages
- 1782-1790
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2095893831
- Cited by
- 350
- References
- 78
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.